|
|
| Line 1: |
Line 1: |
| __NOTOC__
| |
| {{Valproate sodium}}
| |
| {{Main|Valproate}}
| |
| {{CMG}}
| |
|
| |
|
| '''''For patient information about Valproate sodium, click [[Valproic Acid (patient information)|here]].'''''
| |
|
| |
| {{SB}} Depacon<sup>®</sup>
| |
|
| |
| ==Overview==
| |
|
| |
| '''Valproic acid''' ('''VPA, Valproate'''), an [[acid]]ic [[chemical compound]], has found clinical use as an [[anticonvulsant]] and [[mood stabilizer|mood-stabilizing]] [[medication|drug]], primarily in the treatment of [[epilepsy]], [[bipolar disorder]], and, less commonly, [[major depressive disorder|major depression]]. It is also used to treat [[migraine headache|migraine]] [[headache]]s. VPA is a liquid at room temperature, but it can be reacted with a base such as sodium hydroxide to form the salt [[sodium valproate]], which is a solid. The acid, salt, or a mixture of the two ([[valproate semisodium]]) are marketed under the various brand names Depakote, Depakote ER, Depakene, Depakine, Depakine Crono (extended release in Spain), Depacon, Dépakine, Valparin, and Stavzor.
| |
|
| |
| Approved uses of the various formulations vary by country; e.g., valproate semisodium is used as a mood stabilizer and also in the US as an anticonvulsant.
| |
|
| |
| VPA is a [[histone deacetylase inhibitor]] and is under investigation for treatment of HIV and various cancers.<ref>{{cite pmid|22318143}}</ref>
| |
|
| |
| ==FDA Package Insert==
| |
|
| |
| ''' [[Valproate sodium indications and usage|Indications and Usage]]'''
| |
| '''| [[Valproate sodium dosage and administration|Dosage and Administration]]'''
| |
| '''| [[Valproate sodium dosage forms and strengths|Dosage Forms and Strengths]]'''
| |
| '''| [[Valproate sodium contraindications|Contraindications]]'''
| |
| '''| [[Valproate sodium warnings and precautions|Warnings and Precautions]]'''
| |
| '''| [[Valproate sodium adverse reactions|Adverse Reactions]]'''
| |
| '''| [[Valproate sodium drug interactions|Drug Interactions]]'''
| |
| '''| [[Valproate sodium use in specific populations|Use in Specific Populations]]'''
| |
| '''| [[Valproate sodium overdosage|Overdosage]]'''
| |
| '''| [[Valproate sodium description|Description]]'''
| |
| '''| [[Valproate sodium clinical pharmacology|Clinical Pharmacology]]'''
| |
| '''| [[Valproate sodium nonclinical toxicology|Nonclinical Toxicology]]'''
| |
| '''| [[Valproate sodium clinical studies|Clinical Studies]]'''
| |
| '''| [[Valproate sodium how supplied storage and handling|How Supplied/Storage and Handling]]'''
| |
| '''| [[Valproate sodium patient counseling information|Patient Counseling Information]]'''
| |
| '''| [[Valproate sodium labels and packages|Labels and Packages]]'''
| |
|
| |
| {|
| |
| | [[File:Valproate sodium warnings.png|800px|thumb]]
| |
| |}
| |
|
| |
| ==Mechanism of Action==
| |
|
| |
| Valproate is believed to affect the function of the [[neurotransmitter]] [[GABA]] in the human brain, making it an alternative to [[Lithium pharmacology|lithium salt]]s in treatment of bipolar disorder. Its mechanism of action includes enhanced neurotransmission of GABA (by inhibiting [[GABA transaminase]], which breaks down GABA). However, several other mechanisms of action in neuropsychiatric disorders have been proposed for valproic acid in recent years.<ref>{{cite pmid|17514356}}</ref>
| |
|
| |
| Valproic acid also blocks [[voltage-gated sodium channel]]s and [[T-type calcium channels]]. These mechanisms make valproic acid a broad-spectrum anticonvulsant drug.
| |
|
| |
| Valproic acid is an [[Enzyme inhibitor|inhibitor]] of the [[enzyme]] [[histone deacetylase 1]] (HDAC1), hence it is a [[histone deacetylase inhibitor]].
| |
|
| |
| ==References==
| |
|
| |
| {{Reflist|2}}
| |
|
| |
| [[Category:Antimigraine drugs]]
| |
| [[Category:Anticonvulsants]]
| |